Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanicemine in Severe Major Depressive Disorder
NCT00781742Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanicemine in major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 3 weeks. Started Oct 2008; status: completed.
02
Drugs
lanicemine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00781742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781742.